Association of stiff-person syndrome with autoimmune endocrine diseases

Table 4 Summary of two stiff person syndrome cases associated with autoimmune diabetes

	Case 1: T1DM	Case 2: LADA
Gender	Female	Male
Age of diagnosis of DM	43	30
Age of diagnosis of SPS	32	33
Age of requirement for insulin	43	42
HbA1c at diagnosis of DM (%)	13.2	13.1
Basal C-peptide (ng/mL)	0.31	0.26
Glucagon-stimulated C-peptide (ng/mL)	0.6	0.41
Initial GAD Ab (U/mL) (Ref < 1 units)1	1496 (before T1DM)	110 (before LADA)
GAD-Ab titer before receiving plasmapheresis (U/mL) (Ref < 5 units)2	> 2000 (after T1DM)	> 2000 (after LADA)
GAD-Ab titer after receiving plasmapheresis (U/mL) (Ref < 5 units)2	> 2000	> 2000
IA2 antibody (U/mL) (Ref < 7.5)	0.97	0.65
Anti-TPO (IU/mL) (Ref < 5.6)	< 1.0	18.81
Medications	Diazepam, clonazepam, baclofen, lamotrigine, azathioprine	Diazepam, clonazepam, baclofen, tizanidine
IVIG	No	Yes (IVIG 0.4/kg/d)
Plasmapheresis	Yes, 10 times	Yes, 15 times

¹Radioimmunoassay;

²Enzyme -linked immunosorbent assay. SPS: Stiff-person syndrome; T1DM: Type 1 diabetes mellitus; LADA: Latent autoimmune diabetes in adults; GAD: Glutamic acid decarboxylase; IA-2: Islet antigen 2; TPO: Thyroid peroxidase; IVIG: Intravenous immunoglobulin.